What happened with FEED today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of ENvue Medical’s product revenue comes from PainShield and its replacement kits. PainShield delivers localized ultrasound through a disposable patch connected to a reusable driver, allowing patients to receive treatment at home or in a clinic. The company sells to patients and to distributors, which buy products at fixed prices and handle local marketing and sales. Continued treatment creates demand for replacement patches. Revenue is concentrated among a few customers, with Ultra Pain Products Inc. its largest customer.
Its other business sells the ENvue System directly to U.S. hospitals. The system tracks a feeding tube’s path in real time to help clinicians place it in patients who need nutritional support. Hospitals buy the navigation equipment and repeatedly order dedicated single-use feeding tubes as needed; some receive equipment without charge when replacing a competitor’s system but still pay for tubes. FDA clearance requires use of ENvue’s own tube and company-provided user training. This business remains in an early commercialization stage and depends on hospitals adopting the system and incorporating it into clinical workflows.
Insurance coverage and reimbursement strongly influence product demand. PainShield requires a prescription in the United States, and the company has not obtained a Medicare reimbursement rate despite receiving a billing code. U.S. promotion of the ENvue System is limited to the adult feeding-tube placement uses covered by its FDA clearance.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ENvue Medical’s growth hinges on hospitals choosing its feeding-tube system over Avanos Medical’s closely competing Cortrak 2, while PainShield remains its largest revenue source.
Cardinal Health competes for hospitals’ feeding-tube purchases: its IRIS Kangaroo uses a camera to guide placement, while ENvue Medical’s system uses electromagnetic navigation. Watch hospital adoption of IRIS Kangaroo as a competitive test for ENvue’s system sales and recurring disposable-tube sales.
Enovis Corporation’s non-surgical pain-management and physical-therapy devices compete for treatment spending with ENvue Medical’s PainShield ultrasound device and disposable patches. Watch Enovis’s Prevention & Recovery business rather than its surgical implants: PainShield and monthly kits supplied 73% of ENvue’s product revenue in the year ended December 31, 2025.
Smith & Nephew competes with ENvue Medical’s NanoVibronix business, which makes non-invasive devices for home pain therapy and biofilm prevention. Smith & Nephew sells a much broader range of medical technologies and services to healthcare customers, so its overall results are a less focused comparison for ENvue than news about competing devices and treatments.
Cardinal Health, Inc. earningsCAH
Cardinal Health’s report will show hospital adoption of its IRIS Kangaroo feeding-tube placement system, a direct alternative that competes with ENvue Medical for system sales and dedicated-tube orders.
Look for Cardinal Health’s IRIS Kangaroo adoption and related system sales or use measures. Faster adoption would show hospitals choosing its camera-guided approach, making it harder for ENvue Medical to win system purchases and the dedicated-tube orders that follow; slower adoption would mean less pressure through this direct competitive channel.
ENvue Medical, Inc. earningsThis company
ENvue Medical, Inc. sells hospitals a feeding-tube navigation system and relies on repeat sales of its dedicated disposable tubes, so this report shows whether adoption is producing recurring business.
Read ENvue system sales alongside sales of its dedicated feeding tubes. Growth in both would show hospitals are not just taking systems but using them, building repeat consumables revenue; system sales rising without tube sales keeping pace would show placements are not yet translating into sustained use.
